Effects of nicotine on cytochrome P450 2A6 and 2E1 activities

British Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2010, Pages 152-159

  Hukkanen, Janne ^d   Jacob Iii, Peyton ^a,b,c   Peng, Margaret ^a,b,c   Dempsey, Delia ^a,b,c   Benowitz, Neal L ^a,b,c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

Chlorzoxazone; Cotinine; CYP2A6; CYP2E1; Nicotine

Indexed keywords

2,4,5,6 TETRADEUTEROCOTININE; 3',3' DIDEUTERONICOTINE; 6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; NICOTINE; NICOTINE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; CENTRAL MUSCLE RELAXANT; COTININE; CYTOCHROME P450; NICOTINIC AGENT; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SMOKING CESSATION; CROSSOVER PROCEDURE; DRUG INTERACTION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; SMOKING; YOUNG ADULT;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CHLORZOXAZONE; COTININE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NICOTINE; NICOTINIC AGONISTS; SINGLE-BLIND METHOD; SMOKING; YOUNG ADULT;

EID: 75149166653     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03568.x     Document Type: Article

References (38)

1. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999 36 : 425 438.
2. Benowitz NL, Peng M, Jacob P III. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003 74 : 468 474.
3. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008 82 : 667 715.
4. Benowitz NL, Jacob P III. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 1993 53 : 316 323.
5. Benowitz NL, Jacob P III. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 2000 67 : 653 659.
6. Lee BL, Benowitz NL, Jacob P III. Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin Pharmacol Ther 1987 41 : 474 479.
7. Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994 56 : 483 493.
8. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996 24 : 1212 1217.
9. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996 277 : 1010 1015.
10. Hukkanen J, Jacob P III., Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005 57 : 79 115.
11. Iscan M, Rostami H, Guray T, Pelkonen O, Rautio A. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 1994 47 : 315 318.
12. Poland RE, Pechnick RN, Cloak CC, Wan YJ, Nuccio I, Lin KM. Effect of cigarette smoking on coumarin metabolism in humans. Nicotine Tob Res 2000 2 : 351 354.
13. Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 2003 63 : 96 104.
14. Crawford EL, Weaver DA, DeMuth JP, Jackson CM, Khuder SA, Frampton MW, Utell MJ, Thilly WG, Willey JC. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis 1998 19 : 1867 1871.
15. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 1999 23 : 991 1007.
16. Howard LA, Miksys S, Hoffmann E, Mash D, Tyndale RF. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003 138 : 1376 1386.
17. Anandatheerthavarada HK, Williams JF, Wecker L. Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem Biophys Res Commun 1993 194 : 312 318.
18. Howard LA, Micu AL, Sellers EM, Tyndale RF. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther 2001 299 : 542 550.
19. Joshi M, Tyndale RF. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab Dispos 2006 34 : 647 652.
20. Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol 2009 609 : 88 95.
21. Jacob P III., Yu L, Wilson M, Benowitz NL. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3′,3′-d2 in humans. Biol Mass Spectrom 1991 20 : 247 252.
22. Lucas D, Ferrara R, Gonzales E, Albores A, Manno M, Berthou F. Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments. Toxicol Lett 2001 124 : 71 81.
23. Zevin S, Jacob P III., Benowitz N. Cotinine effects on nicotine metabolism. Clin Pharmacol Ther 1997 61 : 649 654.
24. Stalhandske T, Slanina P. Effect of nicotine treatment on the metabolism of nicotine in the mouse liver in vitro. Acta Pharmacol Toxicol (Copenh) 1970 28 : 75 80.
25. Denton TT, Zhang X, Cashman JR. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 2004 67 : 751 756.
26. Stalhandske T, Slanina P. Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. Toxicol Appl Pharmacol 1982 65 : 366 372.
27. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schuetz EG. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 2004 199 : 251 265.
28. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, Yokoi T. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 2006 319 : 693 702.
29. Kyerematen GA, Morgan M, Warner G, Martin LF, Vesell ES. Metabolism of nicotine by hepatocytes. Biochem Pharmacol 1990 40 : 1747 1756.
30. Asimus S, Hai TN, Van Huong N, Ashton M. Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 2008 64 : 283 292.
31. Bhagwat SV, Vijayasarathy C, Raza H, Mullick J, Avadhani NG. Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain. Biochem Pharmacol 1998 56 : 831 839.
32. Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J Pharmacol Exp Ther 2003 306 : 941 947.
33. Lee AM, Yue J, Tyndale RF. In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment. Drug Metab Dispos 2006 34 : 1508 1515.
34. Van Vleet TR, Bombick DW, Coulombe RA Jr. Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol Sci 2001 64 : 185 191.
35. Draper AJ, Madan A, Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 1997 341 : 47 61.
36. Bu HZ, Magis L, Knuth K, Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001 15 : 741 748.
37. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005 24 : 123 132.
38. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005 19 : 2651 2658.